Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
47 hedge funds and large institutions have $14.1M invested in Titan Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 8 closing their positions.
18,367% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $6K
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
0% more funds holding
Funds holding: 47 → 47 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
17% less capital invested
Capital invested by funds: $17M → $14.1M (-$2.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$724K |
| 2 |
Renaissance Technologies
New York
|
+$690K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$404K |
| 4 |
SO
STRS Ohio
Columbus,
Ohio
|
+$370K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$303K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$305K |
| 2 |
Millennium Management
New York
|
-$146K |
| 3 |
SIM
Spark Investment Management
New York
|
-$141K |
| 4 |
State Street
Boston,
Massachusetts
|
-$101K |
| 5 |
SG Americas Securities
New York
|
-$96K |
TTNP Hedge Fund Activity: Q4 2016 in Review
47 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2016, worth a combined $14.1M — down 17% from $17M a quarter earlier.
Fund positioning in TTNP was balanced in Q4 2016: 8 funds opened new positions, 8 closed out, 11 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $724K. The largest seller was AQR Capital Management, exiting entirely with an estimated $305K sold.
- 47 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $14.1M of Titan Pharmaceuticals stock for Q4 2016, down 17% quarter-over-quarter.
- 8 funds opened new Titan Pharmaceuticals positions in Q4 2016 and 8 closed out, a net change of 0 holders.
- The largest Titan Pharmaceuticals buyer in Q4 2016 was Morgan Stanley, an estimated $724K added.
- The largest Titan Pharmaceuticals seller in Q4 2016 was AQR Capital Management, an estimated $305K sold.
Based on aggregated 13F filings for Q4 2016.